title: [Do drug-eluting stents influence the spectrum of coronary artery bypass surgery?].
abstract: BACKGROUND
  The number of surgical coronary revascularization procedures is static and even declining. Since the introduction of drug eluting stents the question arose whether this will have an impact on the spectrum of surgical coronary revascularization procedures.
  Bypass surgery is a routine procedure for the treatment of coronary artery disease with good results. Studies have shown that there is a benefit in favor of surgery compared to interventional cardiologic procedures. DRUG-ELUTING STENTS: In recent studies a new generation of stents, drug-eluting stents, have proven to have a significant better patency rate than common stents. However, to date there are no studies which show a benefit compared to surgery given the same indication for treatment.
  
  
  CONCLUSIONS
  Therefore, the question whether drug-eluting stents have an impact on the spectrum of bypass surgery cannot be fully answered at present.
authors.affiliation: Klinik für Herz- und Thorakale Gefässchirurgie, Herzzentrum Dresden GmbH, Universitätsklinik, Dresden. monika.webre.hkz_dd@t-online.de
authors.forename: Klaus
authors.initials: K
authors.lastname: Matschke
authors.forename: Sems Malte
authors.initials: SM
authors.lastname: Tugtekin
authors.forename: Utz
authors.initials: U
authors.lastname: Kappert
authors.forename: Friedrich
authors.initials: F
authors.lastname: Jung
authors.forename: Jai-Wun
authors.initials: JW
authors.lastname: Park
authors.forename: Michael
authors.initials: M
authors.lastname: Knaut
mesh_terms: D000287:Administration, Topical; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D020099:Coated Materials, Biocompatible; D001026:Coronary Artery Bypass; D023903:Coronary Restenosis / Q000175:diagnosis / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000175:diagnosis / Q000628:therapy*; D003331:Coronary Vessels / Q000187:drug effects; D019544:Equipment Failure Analysis; D006801:Humans; D008855:Microscopy, Electron, Scanning; D017239:Paclitaxel / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D017239:Paclitaxel; D020123:Sirolimus